Maintenance of Clinical Response With Continued Risankizumab Treatment for Moderate-to-Severe Psoriasis Through 304 Weeks: Interim Analysis of the LIMMitless Open-Label Extension Study. J of Skin. 2023;7(6):s258. doi:10.25251/skin.7.supp.258